UroGen Pharma GAAP EPS of -$1.18 beats by $0.12, revenue of $16.6M misses by $0.68M, reaffirms FY revenue guidance

Aug. 11, 2022 8:03 AM ETUroGen Pharma Ltd. (URGN)By: Deepa Sarvaiya, SA News Editor

UroGen Pharma press release (NASDAQ:URGN): Q2 GAAP EPS of -$1.18 beats by $0.12.
Revenue of $16.6M (+27.4% Y/Y) misses by $0.68M.
The company reaffirmed 2022 full-year revenue guidance of $70-$80 million vs consensus of $75.21M

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.